New combo pill aims to extend life in tough bile duct cancer
NCT ID NCT06622057
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 5 times
Summary
This study tests whether adding an experimental drug (D07001) to standard chemotherapy (capecitabine) helps people with advanced bile duct cancer live longer. About 195 adults whose cancer has not responded to earlier treatments will receive either D07001 or a placebo, plus capecitabine. The goal is to see if the combination improves overall survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMPULLARY CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Kaohsiung Medical University Chung-Ho Memorial Hospital
NOT_YET_RECRUITINGKaohsiung City, 807, Taiwan
-
Mount Sinai Medical Center
RECRUITINGMiami Beach, Florida, 33140, United States
-
The University of Arizona Cancer Center
RECRUITINGTucson, Arizona, 85724, United States
-
University Hospital Cleveland Medical Center
RECRUITINGCleveland, Ohio, 44106, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a vaccine help fight Hard-to-Treat cancers?
- Can a smaller incision offer the same cancer surgery outcome?
- Can matching cancer drugs to tumor genes prevent biliary tract cancer return?
- Can a smart drug home in on Hard-to-Treat GI cancers?
- Can a dual immune booster plus chemo shrink hard-to-treat bile duct tumors?
- Can matching drugs to tumor genes beat biliary cancer?